Journal of Urologic Oncology

Editorial

March 31, 2024

JUO, the Journal of Urologic Oncology, Celebrates Its Second Anniversary

Cheol Kwak

J Urol Oncol. 2024;22(1):1-3.

Invited Review

March 31, 2024

Prostate-Specific Antigen-Based Prostate Cancer Screening: One for All or Individualized for Each Race? – A Narrative Review

Chang Wook Jeong

J Urol Oncol. 2024;22(1):4-10.

Prostate cancer (PCa) is the second most common cancer globally. However, significant disparities in incidence and mortality exist between countries, especially between Western and Asian regions. This review discusses the...

Invited Review

March 31, 2024

Multidisciplinary Team Approach in Prostate-Specific Membrane Antigen Theranostics for Prostate Cancer: A Narrative Review

Minseok Suh, Gi Jeong Cheon

J Urol Oncol. 2024;22(1):11-20.

In managing prostate cancer, the integration of multidisciplinary team (MDT) with prostate-specific membrane antigen (PSMA) theranostics marks a significant advancement, addressing the disease's spectrum from indolent forms to aggressive metastatic...

Original Article

March 31, 2024

High-Grade Late Urinary Toxicity Following Salvage Radiotherapy After Radical Prostatectomy: A Retrospective Cohort Study

Seung-Kwon Choi, Myong Kim, Sang Mi Lee, et al.

J Urol Oncol. 2024;22(1):21-28.

Purpose: To find out the incidence and predictors for late high-grade genitourinary (GU) toxicity following salvage radiotherapy (SRT), we investigated the consecutive patients who were treated with SRT after radical...

Original Article

March 31, 2024

Enzalutamide Maintenance Following Docetaxel in Metastatic Castration-Naive Prostate Cancer: A Pilot Feasibility Study

Sung Hee Lim, Sung Wook Cho, Jae Hoon Chung, et al.

J Urol Oncol. 2024;22(1):29-33.

Purpose: To assess the feasibility and short-term efficacy of maintenance enzalutamide following first-line docetaxel plus androgen deprivation therapy (ADT) in patients with high-volume, metastatic castration-naive prostate cancer (mCNPC). Materials and Methods:...

Systemic Review and Meta-analysis

March 31, 2024

Targeted Therapy Following Metastasectomy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis

Hui Mo Gu, Seung Il Jung, Dongdeuk Kwon, et al.

J Urol Oncol. 2024;22(1):34-41.

Purpose: The aim of this study was to assess the effects of tyrosine kinase inhibitors (TKIs) following metastasectomy in patients with metastatic renal cell carcinoma (mRCC). Materials and Methods: A systematic...

Original Article

March 31, 2024

Global Renal Cell Carcinoma Research Trends Over 30 Years: A PRISMA-Compliant Bibliometric Analysis

Jung Hoon Kim, Ji Woong Hwang

J Urol Oncol. 2024;22(1):42-51.

Purpose: Renal cell carcinoma (RCC) is a relatively common malignancy of the urinary tract. Over the past few decades, methodologies for diagnosing and managing patients with RCC have shown various...

Original Article

March 31, 2024

Prognostic Factors and Cancer-Specific Survival of Surgically Managed Renal Cell Carcinoma With Venous Thrombus: A 30-Year Experience at a Tertiary Referral Center

Hyun Young Lee, Yunjoong Kim, Bumjin Lim, et al.

J Urol Oncol. 2024;22(1):52-58.

Purpose: This study investigated the prognostic factors and cancer-specific survival (CSS) of patients who had renal cell carcinoma (RCC) with venous thrombus and underwent radical nephrectomy with thrombectomy (RNTx). Materials and...

Original Article

March 31, 2024

Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study

Joohyun Hong, Ghee Young Kwon, Minyong Kang, et al.

J Urol Oncol. 2024;22(1):59-67.

Purpose: TFE3-rearranged/TFEB-altered renal cell carcinoma (RCC) is a rare subtype of RCC. Due to its rarity, there is an unmet medical need for effective therapies in advanced settings. The study...

Invited Review

March 31, 2024

Nephron-Sparing Surgery for Upper Urinary Tract Urothelial Carcinoma

Sung Han Kim, Ilma S. Savul, Seth P. Lerner

J Urol Oncol. 2024;22(1):68-77.

Radical nephroureterectomy (RNU) remains the gold standard for the surgical management of upper tract urothelial carcinoma (UTUC) from the ureterovesical junction to the renal pelvis. However, the removal of the...

Systemic Review and Meta-analysis

March 31, 2024

Poorer Outcomes in Bladder Cancer Patients With Diabetes: A Systematic Review and Meta-analysis Addressing Over 226,472 Bladder Cancer Patients

Stefani Frost, Parisa Ziarati, Ryan Moen, et al.

J Urol Oncol. 2024;22(1):78-94.

Purpose: Diabetes mellitus, a frequent comorbid condition in cancer patients, has been shown to increase risk of all-site cancer mortality. This relationship has not been systematically studied in bladder cancer...

Erratum

March 31, 2024

Declaration of Conflict of Interest for Editorial Board Members’ Articles

J Urol Oncol. 2024;22(1):95-96.

Current Issue: Volume 22(1); Mar 2024

This archive contains links to the full-text of all issues.

Current issue

Volume 22(1); March

All issues

Vol. 22
2024

v.22(1) Mar 2024

Vol. 21
2023

v.21(1) Mar 2023

v.21(2) Jul 2023

v.21(3) Nov 2023

The Korean Journal of Urological Oncology2003 (v1 n1) to 2022 (v22 n4)

Vol. 20
2022

v.20(1) Feb 2022

v.20(2) May 2022

v.20(3) Aug 2022

v.20(4) Nov 2022

Vol. 19
2021

v.19(1) Feb 2021

v.19(2) May 2021

v.19(3) Aug 2021

v.19(4) Nov 2021

Vol. 18
2020

v.18(1) Apr 2020

v.18(2) Aug 2020

v.18(3) Dec 2020

Vol. 17
2019

v.17(1) Apr 2019

v.17(2) Aug 2019

v.17(3) Dec 2019

Vol. 16
2018

v.16(1) Apr 2018

v.16(2) Aug 2018

v.16(3) Dec 2018

Vol. 15
2017

v.15(1) Apr 2017

v.15(2) Aug 2017

v.15(3) Dec 2017

Vol. 14
2016

v.14(1) Apr 2016

v.14(2) Aug 2016

v.14(3) Dec 2016

Vol. 13
2015

v.13(1) Apr 2015

v.13(2) Aug 2015

v.13(3) Dec 2015

Vol. 12
2014

v.12(1) Apr 2014

v.12(2) Aug 2014

v.12(3) Dec 2014

Vol. 11
2013

v.11(1) Apr 2013

v.11(2) Aug 2013

v.11(3) Dec 2013

Vol. 10
2012

v.10(1) Apr 2012

v.10(2) Aug 2012

v.10(3) Dec 2012

Vol. 9
2011

v.9(1) Apr 2011

v.9(2) Aug 2011

v.9(3) Dec 2011

Vol. 8
2010

v.8(1) Apr 2010

v.8(2) Aug 2010

v.8(3) Dec 2010

Vol. 7
2009

v.7(1) Apr 2009

v.7(2) Aug 2009

v.7(3) Dec 2009

Vol. 6
2008

v.6(1) Apr 2008

v.6(2) Aug 2008

v.6(3) Dec 2008

Vol. 5
2007

v.5(1) Apr 2007

v.5(2) Aug 2007

v.5(3) Dec 2007

Vol. 4
2006

v.4(1) Jun 2006

v.4(2) Dec 2006

Vol. 3
2005

v.3(1) Jun 2005

v.3(2) Dec 2005

Vol. 2
2004

v.2(1) Mar 2004

v.2(2) Jun 2004

v.2(3) Sep 2004

v.2(4) Dec 2004

Vol. 1
2003

v.1(1) Mar 2003

v.1(2) Jun 2003

v.1(3) Sep 2003

v.1(4) Dec 2003

Journal of
Urologic Oncology

Print ISSN: 2951-603X
Online ISSN: 2982-7043

4,141	New Drugs for Bacillus Calmette Guérin-Unresponsive Nonmuscle Invasive Bladder Cancer
3,841	The Important Role of Poly ADP-Ribose Polymerase Inhibitor in Prostate Cancer
3,472	The Present and Future of Intravesical Therapy in Bladder Cancer
3,030	Trends of First-Line Targeted Therapy in Korean Patients With Metastatic Clear Cell Renal Cell Carcinoma: Sunitinib Versus Pazopanib, a Multicenter Study
2,882	Is Cytoreductive Nephrectomy Still Beneficial for Patients With Metastatic Renal Cell Carcinoma in the Contemporary Immunotherapy Era?

Cited By 4	Epidemiology of Urologic Cancer in Korea: Nationwide Trends in the Last 2 Decades
Cited By 2	An Update of Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer
Cited By 2	Complex Epidemiology of Prostate Cancer in Asian Countries
Cited By 2	Prostate Imaging and Reporting and Data System Version 2.1: Limitations for Clinical Use
Cited By 2	Influence of Body Composition on the Perioperative and Survival Outcomes of Renal Cell Carcinoma